Speciality Medicines Limited is a pharmaceutical firm established on February 5, 2021, initially operating as a private limited company and later converted into a public limited entity on June 25, 2024. The promoters, Parth B Goyani and Goyani Sumit Babubhai, bring over 13 years of combined industry expertise, positioning the company as a key player in the marketing and distribution of specialized pharmaceuticals domestically and internationally, spanning over 35 countries.
The company's core business revolves around offering finished formulations of specialty pharmaceuticals, including capsules, injections, tablets, creams, gels, eye drops, inhalers, nasal sprays, and more. Its diverse portfolio prioritizes therapeutic areas such as oncology, immunology, neurology, and rare diseases, addressing complex chronic conditions to improve patient health outcomes worldwide. Speciality Medicines engages in collaborations with overseas distributors who maintain relationships with health ministries, government agencies, and private hospitals, further strengthening their global reach.
In line with its expansion strategy, Speciality Medicines Limited is planning an Initial Public Offering (IPO) of up to 23,00,000 equity shares through direct issuance. This move supports its ambition to scale operations and establish itself further as a prominent provider of innovative specialty pharmaceuticals in underserved therapeutic areas.
